{
  "id": 20716180,
  "title": "Health ministry proposes amendment to drug rules to bring antimicrobials under regulatory oversight",
  "url": "https://urgent.news/2026/11/19/health-ministry-proposes-amendment-to-drug-rules-to-bring",
  "topic": "world",
  "section": "World",
  "published": "2026-11-19T07:00:23.000Z",
  "source": {
    "name": "Hindustan Times",
    "slug": "hindustan-times",
    "url": "https://www.hindustantimes.com/india-news/health-ministry-proposes-amendment-to-drug-rules-to-bring-antimicrobials-under-regulatory-oversight-101795071623586.html"
  },
  "original_language": "en",
  "account": "The Ministry of Health and Family Welfare in India has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under the Central regulatory framework that governs new drugs. This move aims to enhance oversight of antimicrobial quality, safety, and efficacy, and tackle the issue of antimicrobial resistance (AMR).\n\nAMR is a significant global public health concern, necessitating coordinated efforts to address it. The G20 New Delhi Leaders' Declaration also emphasized the importance of addressing AMR through a One Health approach, which involves collaboration between humans, animals, and the environment.\n\nThe proposed amendment arises from concerns over the granting of manufacturing licenses for antimicrobial products without sufficient regulatory scrutiny. This includes the need for assessments such as bioavailability/bioequivalence and stability studies, which could impact the quality, safety, and efficacy of these products. Unreliable or ineffective antimicrobials can contribute to the emergence and spread of AMR, risking patient safety.\n\nUnder the proposed amendment, manufacturers would need to seek approval from the Central Licensing Authority (CLA) before applying for a manufacturing license from the State Licensing Authority (SLA). This additional regulatory step is expected to bolster Central regulatory oversight and ensure the quality, safety, and efficacy of antimicrobial products.\n\nThe draft notification, released on November 6, is open for objections and suggestions from stakeholders and the public before the Centre finalizes the proposed amendment. Antimicrobials are substances that kill microorganisms or inhibit their growth, encompassing medicines for treating or preventing infections, as well as topical agents for reducing microbes on skin or surfaces.",
  "summary": null,
  "key_points": [
    "India's health ministry proposes amendment to New Drugs and Clinical Trials Rules, 2019.",
    "Antimicrobials to be brought under Central regulatory framework for quality, safety, efficacy.",
    "Amendment aims to tackle antimicrobial resistance (AMR) and ensure patient safety."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}